ReviewCancers2024
The Multidisciplinary Approach and Surgical Management of GE Junction Adenocarcinoma.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Development and validation of a novel perioperative risk model for anastomotic leakage after esophagectomy using a nationwide web-based database.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Survival Comparison of Proximal and Total Gastrectomy after Neoadjuvant Therapy in Siewert Type II/III Gastric Adenocarcinoma: A Real-World Multicenter Cohort Study.Annals of surgical oncology · 2026Article
- Perioperative management of non-metastatic gastroesophageal cancer in a Philippine university hospital: a 10-year experience.World journal of surgical oncology · 2026Article
- Isolated serosal liver infiltration mimicking cirrhosis in gastroesophageal junction adenocarcinoma: A report of 2 cases.Radiology case reports · 2026Article
- An Evolutionary Research Framework for the Tumor Microenvironment in Gastric Cancer.Journal of inflammation research · 2026Article
- Intratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinoma.Oncoimmunology · 2025Article
- Multi-omic profiling identifies KRT1 as a predictor of immune infiltration and prognosis in gastroesophageal junction cancer.Functional & integrative genomics · 2025Article
- Improving Perioperative Care in Gastric Surgery: Insights from the EUropean PErioperative MEdical Networking (EUPEMEN) Project.Journal of clinical medicine · 2025Article
- Shaping new paths in clinical trial design to address alcohol use disorders and alcohol-associated liver disease.Nature reviews. Gastroenterology & hepatology · 2024Article
- Development and validation of a preoperative model for predicting positive proximal margins in adenocarcinoma of the esophagogastric junction and assessing safe margin distance.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal (GE) junction adenocarcinoma is an aggressive malignancy of growing incidence and is associated with public health issues such as obesity and GERD. Management has evolved over the last two decades to incorporate a multidisciplinary approach, including endoscopic intervention, neoadjuvant chemotherapy/chemoradiation, and minimally invasive or more limited surgical approaches. Surgical approaches include esophagectomy, total gastrectomy, and, more recently, proximal gastrectomy. This review analyzes the evidence for and applicability of these varied approaches in management, as well as areas of continued controversy and investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.